Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR): After a Federal Drug Administration panel recommended approval of Lomitapide, Deutsche Bank raised their price target for shares of Aegerion Pharmaceuticals, Inc. The firm believes the drug will be approved and keeps a Buy rating on the stock.
Dollar General Corporation (NYSE:DG): During a field trip to the company’s headquarters, Deutsche Bank said that Dollar General Corporation management did not discuss current trends concerning their own business. The firm indicated that management’s comments mirror statements made by the company earlier this year. Deutsche recommends using the pullback in shares of Dollar General as a buying opportunity and keeps a Buy rating on the name.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
SodaStream International Ltd. (NASDAQ:SODA): William Blair said their meeting in Europe with SodaStream International Ltd.’s management indicated that the company’s fundamentals remain strong. The firm finds the stock attractively valued and believes investors could be rewarded in the near-term with a positive third quarter report and constructive outlook.
Obagi Medical Products, Inc. (NASDAQ:OMPI): Due to a slower than expected transition towards an e-commerce platform, Canaccord lowered Obagi Medical Products, Inc.’s sales growth estimates for 2013. Shares remain Buy rated.
Don’t Miss: Will Green Mountain Expand Overseas?